Related Experiment Video

Updated: Jun 22, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Targeting the Met signaling pathway in renal cancer

Alessio Giubellino1, W Marston Linehan, Donald P Bottaro

  • 1Urologic Oncology Branch, CCR, National Cancer Institute, Bethesda, MD 20892-21107, USA.

Expert Review of Anticancer Therapy
|June 6, 2009
PubMed

Insights

Renal cell carcinoma (RCC) is a common kidney cancer. Targeting the Met signaling pathway shows promise for developing new, selective RCC therapies currently in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Renal cell carcinoma (RCC) is the most common kidney cancer, with increasing incidence and significant mortality.
  • RCC accounts for 3% of adult malignancies, causing over 100,000 deaths globally each year.
  • Advances in understanding RCC's molecular basis are driving the development of targeted therapies.

Purpose of the Study:

  • To review the role of the Met signaling pathway in renal cell carcinoma (RCC) oncogenesis.
  • To explore how understanding Met signaling has led to novel therapeutic strategies for kidney cancer.
  • To highlight the development of potent and selective drug candidates targeting the Met pathway.

Main Methods:

  • Literature review focusing on Met signaling in RCC.
  • Analysis of molecular mechanisms underlying RCC development.
  • Examination of clinical trial data for Met-targeted therapies.

Main Results:

  • The Met signaling pathway plays a crucial role in RCC oncogenesis.
  • Met has emerged as a significant molecular target for kidney cancer therapy.
  • Several drugs targeting the Met pathway are progressing through clinical trials.

Conclusions:

  • Understanding the Met signaling pathway is key to developing effective RCC treatments.
  • Targeting Met offers a promising strategy for novel and selective kidney cancer therapies.
  • Ongoing clinical trials are evaluating the efficacy of Met-targeted drugs for RCC.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...